GT200900194A - Derivados de espirocromanona sustituida como inhibidores de acc. - Google Patents

Derivados de espirocromanona sustituida como inhibidores de acc.

Info

Publication number
GT200900194A
GT200900194A GT200900194A GT200900194A GT200900194A GT 200900194 A GT200900194 A GT 200900194A GT 200900194 A GT200900194 A GT 200900194A GT 200900194 A GT200900194 A GT 200900194A GT 200900194 A GT200900194 A GT 200900194A
Authority
GT
Guatemala
Prior art keywords
spirochromanone
derivatives
replaced
acc inhibitors
maligno
Prior art date
Application number
GT200900194A
Other languages
English (en)
Spanish (es)
Inventor
Tomoharu Iino
Hideki Jona
Jun Shibata
Tadashi Shimamura
Takeru Yamakawa
Lihu Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900194A publication Critical patent/GT200900194A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
GT200900194A 2007-01-12 2009-07-06 Derivados de espirocromanona sustituida como inhibidores de acc. GT200900194A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88030207P 2007-01-12 2007-01-12

Publications (1)

Publication Number Publication Date
GT200900194A true GT200900194A (es) 2015-03-09

Family

ID=39297859

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900194A GT200900194A (es) 2007-01-12 2009-07-06 Derivados de espirocromanona sustituida como inhibidores de acc.

Country Status (27)

Country Link
US (1) US8093389B2 (enExample)
EP (1) EP2111406B1 (enExample)
JP (1) JP5319550B2 (enExample)
KR (1) KR20090108022A (enExample)
CN (1) CN101631791B (enExample)
AR (1) AR064824A1 (enExample)
AU (1) AU2008205638B2 (enExample)
BR (1) BRPI0806531A2 (enExample)
CA (1) CA2674573C (enExample)
CL (1) CL2008000067A1 (enExample)
CO (1) CO6190611A2 (enExample)
CR (1) CR10944A (enExample)
DO (1) DOP2009000176A (enExample)
EC (1) ECSP099503A (enExample)
GT (1) GT200900194A (enExample)
HN (1) HN2009001276A (enExample)
MA (1) MA31108B1 (enExample)
MX (1) MX2009007502A (enExample)
NI (1) NI200900139A (enExample)
NZ (1) NZ577825A (enExample)
PE (1) PE20081559A1 (enExample)
RU (1) RU2009130736A (enExample)
SG (1) SG177977A1 (enExample)
TW (1) TW200836727A (enExample)
UA (1) UA103990C2 (enExample)
WO (2) WO2008088688A1 (enExample)
ZA (1) ZA200904138B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613427A2 (pt) * 2005-07-19 2012-10-30 Merck & Co Inc composto ou seu sal ou éster, composição farmacêutica, agente terapêutico, e , uso do composto ou seu sal ou éster
AU2008205642B2 (en) * 2007-01-12 2013-06-06 Msd K.K. Spirochromanon derivatives
US7946800B2 (en) 2007-04-06 2011-05-24 Brooks Automation, Inc. Substrate transport apparatus with multiple independently movable articulated arms
US8267636B2 (en) 2007-05-08 2012-09-18 Brooks Automation, Inc. Substrate transport apparatus
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8318762B2 (en) * 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
JP5501256B2 (ja) 2008-07-04 2014-05-21 Ｍｓｄ株式会社 新規スピロクロマノンカルボン酸
EP2310015A4 (en) * 2008-07-14 2011-10-26 Cropsolution Inc ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF
SG171765A1 (en) 2008-11-20 2011-07-28 Genentech Inc Pyrazolopyridine pi3k inhibitor compounds and methods of use
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
EP2519288B1 (en) * 2009-12-31 2016-04-13 DEKA Products Limited Partnership Infusion pump assembley
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
CN101851237B (zh) * 2010-06-18 2012-10-17 南方医科大学 一种螺环化合物及其制备方法和应用
RS55224B1 (sr) 2010-09-30 2017-02-28 Pfizer N1-pirazolospiroketon acetil-coa karboksilaza inhibitori
PT2632925E (pt) 2010-10-29 2015-09-01 Pfizer Inibidores de n1/n2-lactama da acetil-coa carboxilase
WO2012077655A1 (ja) * 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
TWI520964B (zh) 2011-02-02 2016-02-11 維泰克斯製藥公司 作為離子通道調節劑之吡咯并吡－螺環哌啶醯胺
AU2012217616B2 (en) 2011-02-18 2017-03-02 Vertex Pharmaceuticals Incorporated Chroman - spirocyclic piperidine amides as modulators of ion channels
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
RS54526B1 (sr) 2011-04-22 2016-06-30 Pfizer Inc. Upotreba derivata pirazolospiroketona kao inhibitora acetil-coa karboksilaze
TW201300393A (zh) * 2011-05-20 2013-01-01 Kowa Co 新穎之螺哌啶衍生物及含有其之醫藥
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9055750B2 (en) 2012-02-03 2015-06-16 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9072301B2 (en) 2012-02-03 2015-07-07 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
HK1221662A1 (zh) 2013-05-10 2017-06-09 Gilead Apollo, Llc Acc抑制剂和其用途
MX2015015422A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
EP3554637A4 (en) 2016-12-14 2020-05-20 89Bio Ltd. SPIROPIPERID DERIVATIVES
CA3068623A1 (en) * 2017-06-30 2019-01-03 Quixgen, Inc. Novel spirolactone compounds
IL318404A (en) * 2022-07-29 2025-03-01 Pfizer NOVEL ACC INHIBITORS
CN119798270B (zh) * 2025-01-06 2026-02-24 中国海洋大学 靶向egfr的小分子化合物及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814983A1 (de) * 1978-04-07 1979-10-18 Bayer Ag Neue chromanon-derivate
JPH03182725A (ja) 1989-12-08 1991-08-08 Internatl Business Mach Corp <Ibm> 非線形光学素子及びその製造方法
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DE69412067T2 (de) 1993-01-28 1999-03-25 Merck & Co., Inc., Rahway, N.J. Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
US5856083A (en) 1994-05-06 1999-01-05 Pharmacopeia, Inc. Lawn assay for compounds that affect enzyme activity or bind to target molecules
US5688997A (en) * 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US6017768A (en) 1994-05-06 2000-01-25 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
CA2189634A1 (en) 1994-05-06 1995-11-16 John J. Baldwin Combinatorial dihydrobenzopyran library
WO1996039140A1 (en) 1995-06-06 1996-12-12 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
GB0003397D0 (en) * 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
WO2002020509A2 (de) 2000-09-06 2002-03-14 Bayer Aktiengesellschaft Arzneimittel gegen virale erkrankungen
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
JP2005320250A (ja) 2002-05-09 2005-11-17 Ajinomoto Co Inc ビスラクトン誘導体及びその医薬組成物としての使用
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
EP1802623A1 (en) * 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
BRPI0518281A2 (pt) 2004-11-18 2008-11-18 Incyte Corp inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
US20090215742A1 (en) 2005-05-03 2009-08-27 Pfizer, Inc. Amide resorcinol compounds
BRPI0613427A2 (pt) * 2005-07-19 2012-10-30 Merck & Co Inc composto ou seu sal ou éster, composição farmacêutica, agente terapêutico, e , uso do composto ou seu sal ou éster
AU2007326950B2 (en) * 2006-11-29 2010-10-14 Pfizer Products Inc. Spiroketone acetyl-CoA carboxylase inhibitors
AU2008205642B2 (en) * 2007-01-12 2013-06-06 Msd K.K. Spirochromanon derivatives

Also Published As

Publication number Publication date
HN2009001276A (es) 2012-01-17
JP2010515733A (ja) 2010-05-13
PE20081559A1 (es) 2008-11-20
ZA200904138B (en) 2010-04-28
MA31108B1 (fr) 2010-01-04
RU2009130736A (ru) 2011-02-20
ECSP099503A (es) 2009-08-28
CN101631791A (zh) 2010-01-20
AR064824A1 (es) 2009-04-29
EP2111406A1 (en) 2009-10-28
JP5319550B2 (ja) 2013-10-16
HK1131136A1 (en) 2010-01-15
TW200836727A (en) 2008-09-16
CR10944A (es) 2009-08-12
AU2008205638B2 (en) 2012-08-16
CO6190611A2 (es) 2010-08-19
EP2111406B1 (en) 2012-10-24
NZ577825A (en) 2012-04-27
BRPI0806531A2 (pt) 2014-04-22
WO2008088689A1 (en) 2008-07-24
CN101631791B (zh) 2012-12-12
UA103990C2 (en) 2013-12-25
MX2009007502A (es) 2009-07-17
NI200900139A (es) 2010-02-24
KR20090108022A (ko) 2009-10-14
US20080171761A1 (en) 2008-07-17
SG177977A1 (en) 2012-02-28
US8093389B2 (en) 2012-01-10
WO2008088688A1 (en) 2008-07-24
CL2008000067A1 (es) 2008-05-16
CA2674573A1 (en) 2008-07-24
CA2674573C (en) 2015-04-14
DOP2009000176A (es) 2009-08-31
AU2008205638A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
GT200900194A (es) Derivados de espirocromanona sustituida como inhibidores de acc.
CL2007003352A1 (es) Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen
ECSP109934A (es) Compuesto - 946
AR063628A1 (es) Compuestos de piridinona utiles para el tratamiento de cancer
CL2007003000A1 (es) Compuestos derivados de biaril eter urea; composicion farmaceutica que los contienen; y su uso para el tratamiento de enfermedades o afecciones asociadas a la actividad de amida hidrolasa de acidos grasos (faah).
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
AR065135A1 (es) Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CO6251239A2 (es) Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo junto con un inhibidor de dpp iv
CL2008002052A1 (es) Compuestos derivados de pirazol, inhibidores de la 11 beta-hidroxi-esteroide-deshidrogenasa; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y uso para la preparacion de medicamentos para el tratamiento de diabetes, obesidad, trastornos de ingestion de comida o dislipidemia
ECSP066302A (es) Omega-carboxiaril-difenil-urea sustituida con flúor para el tratamiento y la prevención de enfermedades y afecciones
CO6650337A2 (es) Derivados de 3- hidroxi-5 -arilisotiazol novedoso
AR061968A1 (es) Ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-i-il-piridin-3-il-amino)-pirimidin-4-iloxi]-piperidin-i-carboxilico, composicion farmaceutica que lo comprende y un metodo de preparacion de la misma y el uso de este compuesto para el tratamiento de trastornos metabolicos
GT200500307A (es) Compuestos quimicos
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
MX374694B (es) USO DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO EN COMBINACIÓN CON INSULINA PARA REDUCIR LA DOSIS DE INSULINA Y PARA MEJORAR EL CONTROL GLUCÉMICO EN PACIENTES CON DIABETES MELLITUS.
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
MX2017007874A (es) Derivado de biarilo como agonista de gpr120.
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
UY30736A1 (es) Compuestos quimicos 537
AR095032A1 (es) Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo